FILE:BMY/BMY-8K-20030926171345.txt.gz
EVENTS:	Financial statements and exhibits	Regulation FD Disclosure
TEXT:
ITEM: Financial statements and exhibits
ITEM: Regulation FD Disclosure
================================================================================ SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 26, 2003 Date of earliest event reported: September 24, 2003 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 1-1136 22-079-0350 (State or other jurisdiction (Commission file (IRS Employer of incorporation) number) Identification Number) 345 Park Avenue New York, NY 10154 (Address of principal executive office) Registrant's telephone number, including area code: (212) 546-4000 ================================================================================
Item 7 (c). Exhibits Exhibit 99 - Press release of Bristol-Myers Squibb Company dated September 24, 2003 announcing the intention to offer convertible senior debentures. Item 9. Regulation FD Disclosure On September 24, 2003, Bristol-Myers Squibb Company issued a press release announcing the intention to offer $1 billion of convertible senior debentures. A copy of the press release is furnished as Exhibit 99 to this report and is incorporated herein by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bristol-Myers Squibb Company, By: /s/ Sandra Leung ------------------------------------- Name: Sandra Leung Title: Secretary Date: September 26, 2003 EXHIBIT INDEX EXHIBIT NO. DESCRIPTION - ----------- ----------- 99 Press Release dated September 24, 2003 of Bristol-Myers Squibb Company

Exhibit 99 FOR IMMEDIATE RELEASE CONTACT: Bonnie Jacobs John Elicker Corporate Affairs Investor Relations 609-252-4089 212-546-3775 bonnie.jacobs@bms.com john.elicker@bms.com BRISTOL-MYERS SQUIBB ANNOUNCES OFFERING OF CONVERTIBLE SENIOR DEBENTURES NEW YORK, NEW YORK (September 24, 2003) -- Bristol-Myers Squibb (NYSE: BMY) announced today that it intends to offer $1 billion of convertible senior debentures through an offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The debentures are expected to have a term of 20 years (with a right by the company to call them after five years, and a right by holders to put their debenture every five years) and will be convertible into Bristol-Myers Squibb common stock, at a price to be determined by negotiations between Bristol-Myers Squibb and the initial purchasers of the debentures. The terms of the offering are expected to include an option exercisable by the initial purchasers to purchase up to an additional $200 million aggregate principal amount of debentures. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities. The offering is being made only to qualified institutional buyers. The convertible senior debentures being offered have not been registered under the United States federal or state securities laws and may
not be offered or sold absent registration or an applicable exemption from the registration requirements. Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve significant risks and uncertainties. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. ###


